author-photo

F Mefti-lacheraf

4

Papers

60

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

2019 The Lancet
Show All
- Source
- Cite
- Save
Citations (47)
GEP01: A phase I study of lapatinib (L) and vinorelbine (VNR) in HER2 overexpressing (HER2+) locally advanced or metastatic breast cancer (LAMBC) patients (pts): A FNCLCC Group of early phase trials study

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2

2012 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (11)
Sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to Her2 status, as primary chemotherapy for localized invasive breast cancer patients: results of the planned interim analysis and analysis of predictive parameters. Supported by Phrc Aom/2002/02117, Pfizer inc., Roche, sanofi-aventis

2007 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (1)